Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche preps filings for Herceptin/Perjeta combination

Roche preps filings for Herceptin/Perjeta combination Potential defence against biosimilar competition. A fixed-dose combination of Roche’s antibody blockbusters Herceptin and Perjeta has cleared a phase 3 trial, promising simpler dosing of the breast cancer drugs – ... At the moment, Herceptin and

The Cystic Fibrosis Buyers’ Club

The Cystic Fibrosis Buyers’ Club cancer drug Perjeta.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

AZ’s bet on Daiichi’s rival to Kadcyla pays off drug trio alongside Herceptin (trastuzumab) and Perjeta (pertuzumab).

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts It’s looking likely to overtake Roche’s older breast cancer Perjeta (pertuzumab), which rose 41% to CHF 868m in the quarter and has been another big growth driver for the

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug trastuzumab) and Perjeta (pertuzumab), and have disease progression after Kadcyla treatment. ... That is however well behind the $7bn and $2.8bn added to the company’s coffers by Herceptin and Perjeta.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics